CAS 51012-32-9|Tiapride
| Common Name | Tiapride | ||
|---|---|---|---|
| CAS Number | 51012-32-9 | Molecular Weight | 328.42700 |
| Density | 1.15 g/cm3 | Boiling Point | 498.1ºC at 760 mmHg |
| Molecular Formula | C15H24N2O4S | Melting Point | 120ºC |
| MSDS | USA | Flash Point | 255.1ºC |
Names
| Name | Tiapride hydrochloride |
|---|---|
| Synonym | More Synonyms |
Tiapride BiologicalActivity
| Description | Tiapride, an atypical neuroleptic agent, is a selective dopamine D2-receptor antagonist with little propensity for causing catalepsy and sedation. The IC50 values of Tiapride are 1440, 45.8, >100, and 11.7 μM for D1; D2; D3; D4, respectively[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Dopamine ReceptorSignaling Pathways >>Neuronal Signaling >>Dopamine ReceptorResearch Areas >>Neurological Disease |
| Target | D2 Receptor:110-320 nM (IC50) D3 Receptor:180 nM (IC50) |
| References | [1]. D H Peters, et al. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs. 1994 Jun;47(6):1010-32. [2]. T Arima, et al. Comparison of effects of tiapride and sulpiride on D-1, D-2, D-3 and D-4 subtypes of dopamine receptors in rat striatal and bovine caudate nucleus membranes. Jpn J Pharmacol. 1986 Jul;41(3):419-23. |
Chemical & Physical Properties
| Density | 1.15 g/cm3 |
|---|---|
| Boiling Point | 498.1ºC at 760 mmHg |
| Melting Point | 120ºC |
| Molecular Formula | C15H24N2O4S |
| Molecular Weight | 328.42700 |
| Flash Point | 255.1ºC |
| Exact Mass | 328.14600 |
| PSA | 87.58000 |
| LogP | 2.82590 |
| InChIKey | JTVPZMFULRWINT-UHFFFAOYSA-N |
| SMILES | CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC |
| Storage condition | 2-8°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 1197 mg/kg
- SEX/DURATION :
- female 38 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina
- REFERENCE :
- THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 30,231,1975
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 850 mg/kg
- SEX/DURATION :
- female 27 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - menstrual cycle changes or disorders
- REFERENCE :
- THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 30,231,1975
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | CV4203800 |
| HS Code | 2924299090 |
Customs
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles9
More Articles| Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 138 , 3221-37, (2015) Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here we provide evidence that activation of serotonergic signalling is... | |
| German insurer finds a third of people over 65 take five or more drugs a day. BMJ 346 , f3905, (2013) | |
| Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology 68 , 143-9, (2013) The present review gives an overview of current pharmacological treatment options of tic disorders and Tourette Syndrome (TS). After a short summary on phenomenology, clinical course and comorbid cond... |
Synonyms
| N-[2-(Diethylamino)ethyl]-5-(methylsulfonyl)-o-anisamide hydrochloride |
| N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide |
| EINECS 256-907-9 |
| N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide |
| MFCD00242730 |
